Hormone Therapy News

A cohort of transgender male adolescents on testosterone therapy had a significant increase in BMI during a mean follow-up of nearly 1 year, a trend not seen in a cohort of BMI-matched cisgender females, according to study data.

Children in Sweden who were treated with recombinant human growth hormone, or rhGH, have an increased risk for cardiovascular events in adulthood vs. controls; however, the absolute risk remains low, according to study data.

Gonadotropin-releasing hormone analogue therapy is linked to improvement in final adult height and reduced BMI in central precocious puberty, but evidence for other key outcomes is “weak” to indicate benefits or adverse effects, data show.

Two professional endocrine societies are formally opposing legislative efforts to block transgender people from accessing gender-affirming medical and surgical care, after dozens of state bills threatened to criminalize such therapies.

Health care inequity, changes resulting from the COVID-19 pandemic, and the future of diabetes care were just some of the topics discussed by experts in Endocrine Today’s 2020 cover stories.

Transgender and gender nonbinary patients who remain on estrogen hormone therapy during gender-affirming surgery do not have an increased risk for venous thromboembolism, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Testosterone therapy with intramuscular testosterone undecanoate did not result in any adverse cardiovascular or prostate events in a cohort of men with obesity, type 2 diabetes and functional hypogonadism, clinical trial data showed.

The COVID-19 pandemic was on the minds of Healio readers for most of 2020, and some of the most-read articles involved research to lessen COVID-19 complications and recommendations for reducing risk for exposure in those with diabetes.

The FDA approved relugolix for the treatment of men with advanced prostate cancer.

Clinicians using mass spectrometry to measure hormone levels should exercise caution when assessing data from postmenopausal women, when very low estradiol levels are difficult to measure accurately.